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A B S T R A C T
Despite legislation to stimulate pediatric drug development through clinical trials, enrolling children in trials
continues to be challenging. Non-investigator (those who have never served as a clinical trial investigator)
providers are essential to recruitment of pediatric patients, but little is known regarding the specific barriers that
limit pediatric providers from participating in and referring their patients to clinical trials. We conducted an
online survey of pediatric providers from a wide variety of practice types across the United States to evaluate
their attitudes and awareness of pediatric clinical trials. Using a 4-point Likert scale, providers described their
perception of potential barriers to their practice serving as a site for pediatric clinical trials.
Of the 136 providers surveyed, 52/136 (38%) had previously referred a pediatric patient to a trial, and only
17/136 (12%) had ever been an investigator for a pediatric trial. Lack of awareness of existing pediatric trials
was a major barrier to patient referral by providers, in addition to consideration of trial risks, distance to the site,
and time needed to discuss trial participation with parents. Overall, providers perceived greater challenges
related to parental concerns and parent or child logistical barriers than study implementation and ethics or
regulatory barriers as barriers to their practice serving as a trial site. Providers who had previously been an
investigator for a pediatric trial were less likely to be concerned with potential barriers than non-investigators.
Understanding the barriers that limit pediatric providers from collaboration or inhibit their participation is key
to designing effective interventions to optimize pediatric trial participation.
1. Introduction
In the United States, the number of registered clinical trials for
adults exceeds the number for children by a factor of 10 [1]. While
clinical trials have long been recognized as the gold standard source of
evidence for medical decision-making, a number of factors have con-
tributed to difficulty in performing clinical trials in children, including:
1) a relatively small population of available participants; 2) the high
cost and lack of incentives for pharmaceutical companies to perform
drug trials; 3) potential legal risk to the pharmaceutical sponsor; 4)
ethical concerns regarding participation of children in trials; and 5) a
lack of adequately trained pediatric investigators [2–4]. Since 1997,
multiple federal policies have attempted to stimulate pediatric drug
development through encouragement of pediatric-specific studies
[5–9]. Despite these incentives, relatively few pediatric trials have been
performed, and many trials have enrolled<100 participants [1].
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Even if sponsors and investigators can overcome the above factors
to launch a pediatric clinical trial, low enrollment can cause even the
best-designed trial to be unable to meet its stated objectives [10]. The
obstacles that prevent recruitment and enrollment of children into
clinical trials are complex and can include a combination of factors
related to the participants, their parents, and their doctors [11,12]. The
role of the non-investigator primary pediatrician or pediatric specialist
is substantial. Families are more likely to participate in trials if ap-
proached by the child's primary physician [13,14]. However, primary
providers may be reluctant to enroll or refer children to trials, which
leads to poor recruitment rates and decreases trial success [15].
Therefore, the design and execution of future pediatric clinical trials
relies heavily on understanding the attitudes of non-investigator pri-
mary providers toward trials. However, little is known regarding the
specific barriers that limit non-investigator pediatric and family prac-
tice providers from participating in and referring their patients to
clinical trials. The purpose of this study was to describe factors influ-
encing providers' awareness and willingness to refer their patients for
pediatric clinical trials and the perceived barriers to their practice
serving as a pediatric clinical trial site.
2. Methods
2.1. Participants
We administered a voluntary online survey in August and
September of 2015 to a convenience sample of medical providers who
provide care and treatment to children. We identified potential parti-
cipants through 2 mechanisms: 1) we partnered with a recruitment firm
to identify family practice physicians and general pediatricians from
their database of United States (US)-based physicians who are inter-
ested and willing to participate in surveys; and 2) we identified phy-
sicians of 6 sections of the American Academy of Pediatrics (AAP),
including Section on Clinical Pharmacology & Therapeutics, Section on
Infectious Diseases, Section on Critical Care, Section on Hospital
Medicine, Section on Advances in Therapeutics and Technology, and
Section on Neonatal-Perinatal Medicine. These sections included pro-
viders who are primarily US-based, although some sections included a
small number of international members. An emailed invitation to par-
ticipate in the survey was sent to potential participants identified by
these 2 mechanisms. Participants were also asked to forward the in-
vitation email and survey link to either other pediatric practitioners.
Any surveys received from providers who did not provide care for
children were excluded. This study received a determination of exempt
status by the Duke University Health System Institutional Review
Board. Participants provided their agreement to participate in the
survey by activating the survey link sent in the invitation email and
initiating the online survey.
2.2. Data collection
When completing the survey, providers were asked to share their
experiences with and perspectives in referring pediatric patients to
clinical trials. Providers were asked to rate the importance of multiple
factors to consider when referring pediatric patients to clinical trials
using a 4-point Likert scale (very important, somewhat important,
somewhat unimportant, unimportant). Participants could also choose
“unsure” if they were not certain of the importance of a factor.
Providers reported whether they had previously served as an in-
vestigator for a pediatric clinical trial. Providers were then asked to
reflect upon the severity of 30 potential barriers to pediatric trial im-
plementation, considering what they anticipated would be barriers at
their site. The specific barriers were identified by the Clinical Trials
Transformation Initiative (CTTI) Antibacterial Drug Development
(ABDD) team members, who include experts in pediatric clinical trials
from the pharmaceutical industry, academia, and the Food and Drug
Administration (FDA). Identified barriers were classified into 4 cate-
gories: study implementation, ethics and regulatory, parental concerns,
and parental and child logistics. Providers used a 4-point Likert scale
(major barrier, moderate barrier, somewhat of a barrier, not a barrier)
to indicate the severity of each barrier. Participants could also choose
“not applicable” if they believed the barrier would not apply to their
site, or “unsure” if they were uncertain of severity of the barrier.
2.3. Data analysis
Descriptive statistics were used to describe the quantitative data and
thematic analysis was used to analyze the open-ended responses. The
providers were divided into 2 groups: those with previous experience as
an investigator for a pediatric clinical trial and those without this ex-
perience. We compared the probability of providers answering “not a
barrier” among these 2 groups using Fisher's exact test. P values <
0.05 were considered to be significant. Analyses were conducted using
SAS 9.4 (SAS Institute Inc. Cary, NC).
3. Results
3.1. Study population
A total of 168 providers participated in the survey. Of these, 32 were
excluded because they were not pediatric providers. Therefore, the final
sample size was 136. Most of the providers practiced either family
medicine (55/136; 40%) or general pediatrics (45/136; 33%). The
majority (110/136; 83%) had practiced medicine for more than 10
years (Table 1).
3.1.1. Experience with referring pediatric patients to clinical trials
Thirty-eight percent (52/136) of providers had previously referred a
pediatric patient to a clinical trial. Of those who had not previously
referred a patient, almost all (76/84; 92%) were not aware of any drug
trials to which they could refer their patients. However, most (65/84;
77%) were interested in learning more about referral to drug trials.
When asked to consider the importance of different factors when re-
ferring their pediatric patients to a clinical trial, providers were in
agreement that it is very important to consider the potential benefits
(120/136; 88%) and potential risks (127/136; 93%). Most providers
also reported that it was either very important (29/136; 21%) or
somewhat important (89/136; 65%) to consider the distance to the
study site, and most believed it was very important (49/136; 36%) or
somewhat important (72/136; 53%) to consider the time needed to
discuss the clinical trials with the parents of their pediatric patients.
Table 1
Pediatric provider characteristics.
Pediatric Provider Characteristics (N = 136) No. (%)
Specialty
Family Medicine 55 (40)
General Pediatrics 45 (33)
Pediatric Hospitalist 21 (15)
Pediatric Infectious Disease 15 (11)
Years practicing medicinea
< 5 years 9 (7)
5-10 years 14 (11)
> 10 years 110 (83)
Approximate distance from practice/institution to the nearest academic medical
center or children's hospital
Practice is located in an academic medical center or
children's hospital
23 (17)
< 30 min 70 (52)
30 min to 2 h 39 (29)
> 2 h 4 (3)
Previous investigator for a pediatric clinical triala 17 (12)
a 3 participants did not answer these questions.
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Responses varied, however, on the importance of the potential to
lose control of the pediatric patients' care. When evaluating the sig-
nificance of this factor when considering whether to refer patients, al-
most equal numbers of providers reported that this factor was very
important (26/136; 19%), somewhat important (35/136; 26%), some-
what unimportant (36/136; 27%), and unimportant (34/136; 25%).
Other barriers that were elicited from multiple providers in free-re-
sponse answers included the level of trust or existing relationship be-
tween the provider and investigator, potential cost and compensation to
the patient, and time spent by the patient and family. Several re-
sponders indicated that referring patients to a study depended on
“clinical importance” of the study and that “the gravity of the condition
being treated” must be weighed against “the time and effort to get the
patient into the study.”
3.1.2. Perceived barriers to serving as a clinical trial site
When asked to consider the barriers they may experience if their
practice became a pediatric clinical trial site, providers reported major
barriers in every category investigated (Fig. 1, Fig. 2). All potential
barriers explored in the survey were classified as at least “somewhat of
a barrier” by the majority of participants. Overall, providers perceived
greater challenges related to parental concerns and parent or child lo-
gistical barriers than study implementation and ethics or regulatory
barriers. When asked to describe other potential barriers not mentioned
in the survey, providers responded that several issues would represent
challenges, including concerns regarding the “effect on my own pro-
ductivity and hence pay,” “divergent parent viewpoints,” and having to
manage and explain “the consequences of a negative outcome [for the
child] despite [the parents] having consented.”
The Effect of Experience as an Investigator on Perceived Barriers.
The majority of providers (119/136; 88%) had never been an in-
vestigator for a pediatric trial, although 49/119 (41%) of these non-
investigator providers reported having considered being an investigator
or having their institution or practice be a clinical trial site. Overall,
providers who had previously been an investigator for a pediatric trial
(17/136, 12%) had a trend toward less concern with potential barriers
than providers who had never been an investigator for a pediatric trial
(Fig. 3). Compared to providers without experience as an investigator,
providers with investigator experience were significantly more likely to
consider the following 2 issues to be “not a barrier”: 1) obtaining
adequate funding to cover research costs (investigators: 3/14 (21%);
non-investigators: 5/113 (4%); P = 0.04), and 2) perception of in-
sufficient study benefits for the child (investigators: 4/15 (27%); non-
investigators: 7/112 (6%); P = 0.03).
4. Discussion
A survey of 136 pediatric providers confirmed the significance of 30
potential barriers to clinical trial implementation identified by a team
of pediatric clinical trial experts. For all 30 of the potential barriers, a
majority of participants indicated that they indeed represented barriers
if they were to get involved in a clinical trial. Providers also reported
additional perceived barriers that were not included in the survey.
Although providers' responses demonstrated the presence of challenges
regarding study implementation and ethics/regulatory issues, providers
reported a higher level of concern regarding parental concerns and
parental/child logistics. These findings are in agreement with previous
studies that have highlighted the importance of the parent's perception
of safety as well as the practical convenience of the trial as major po-
tential barriers [11,16].
To our knowledge, this study is the first to compare perceptions of
barriers to implementation of pediatric clinical trials between pediatric
providers with and without experience as pediatric clinical trial in-
vestigators. Study results showed that providers with experience as
pediatric clinical trial investigators were likely to affirm the presence of
the suggested potential barriers to pediatric clinical trials. These re-
sponses may reflect that these investigators have previously en-
countered these issues during their prior participation in clinical trials.
However, having had experience as an investigator was associated with
higher likelihood of classification of several potential issues as “not a
barrier.” It is possible that participants with previous experience as an
investigator are simply more likely to work in a favorable clinical or
institutional environment. Thus, it is understandable that providers
with investigator experience might report fewer concerns, particularly
related to study implementation and ethics/regulatory barriers. On the
other hand, providers with experience as clinical trial investigators also
Fig. 1. Provider perceptions of potential study implementation and ethics regulatory barriers to pediatric clinical trial implementation.
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Fig. 2. Provider perceptions of potential parental concerns and parent or child logistical barriers to pediatric clinical trial implementation.
Fig. 3. Effect of investigator experience on perceived barriers. *P < 0.05 between groups (previous investigator vs. not a previous investigator).
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trended toward being more likely to report parental concerns and
parent/child logistical issues as “not a barrier.” This finding may reflect
some degree of overestimation of these barriers by providers who do
not have previous experience as investigators. However, 83% of the
survey participants had been in practice for more than 10 years with
only 12% having participated in studies, suggesting that many practices
may not show interest or have been given adequate opportunities in
clinical research.
Previous work has shown that involvement of community-based
sites is critical to the success of clinical trials. The majority (83%) of the
participants in our study were community-based providers (not located
in an academic center or children's hospital). In one study that surveyed
parents of children who were being asked to participate in a clinical
trial at the time of cardiac surgery, 56% of parents preferred that their
child's own cardiologist or cardiothoracic surgeon explain the details of
the study, compared to 23% preferring the principal investigator and
3% preferring the research coordinator [13]. Another survey of a so-
cioeconomically diverse population showed that parents reported being
most likely to allow their child to participate in research if approached
by their child's own doctor [14]. Involvement of community sites in
recruitment has also been shown to increase trial recruitment rates,
particularly in minority/underserved populations. In one study, the
authors employed new strategies that focused on location, cultural
competency, and community-based research methodologies [17]. Fol-
lowing this intervention, the authors reported a 62% increase in the
enrollment of black participants in clinical research. Studies in both
adults and children have shown that referral by primary pediatric
providers to clinical trial centers is vital to ensuring clinical trial re-
cruitment [18,19]. From these previous studies, the importance of
primary pediatric provider involvement in clinical research is clear.
Knowledge of which barriers are most important to pediatric pro-
viders, including those identified in our study, is key to the design of
interventions that can reduce the impact of these barriers, leading to
more successful clinical trials. The best method for addressing these
barriers likely lies in a multi-targeted approach. A first step in any
clinical research endeavor involves establishing a trusting relationship
between the principal investigator and the clinical providers. Multiple
participants in our survey highlighted the importance of this relation-
ship, especially since it was so imperative to the providers to have
understanding of the importance of the trial before investing the time
and effort into recruiting their own patients.
Other approaches to reduce these barriers include improvements in
the compensation of sites so that logistical challenges (facilities, ap-
propriate staff training, clinical time for study visits) can be overcome.
Interestingly, the providers surveyed in our study were interested in
compensation not only for themselves and their staff but also the par-
ticipants' families. The question of incentives for pediatric research
participation is complex; incentive and payment practices are widely
inconsistent, and AAP and federal guidelines take different approaches
regarding how and when to approach this subject with families
[20–24]. If more overarching, standard guidelines for family incentives
and payment could be developed, this could result in improved per-
ceptions of this issue among providers and potentially lead to their
increased involvement in clinical trials.
Perhaps the most important strategy for reducing perceived barriers
is education for providers at potential clinical trial sites. Most providers
were unaware of community-based pediatric drug trials in progress in
which their pediatric patients could potentially participate, so dis-
semination of information to these providers is an essential step. It is
encouraging that the majority of providers who had not referred pa-
tients to clinical trials were willing to consider participation in the fu-
ture. With visits to potential sites and other methods of communication
between study personnel and the sites, study coordinating centers could
facilitate development of methods that sites can use to overcome po-
tential logistical problems. Site visits and other methods of site edu-
cation have been shown previously to increase patient recruitment rates
in both adult and pediatric multi-center randomized trials [25,26]. In
addition, coordinating centers may be able to develop and teach new
approaches to improve feasibility of trials, such as the use of mobile and
web-based technology to conduct study visits and procedures remotely
[27–29]. If coordinating centers were able to take full advantage of
these educational strategies, the gap in perceptions between providers
with and without previous investigator experience could be minimized.
The strengths of our study include the large number of pediatric
providers that participated in the survey and the detail with which we
were able to evaluate multiple categories of barriers. We were able to
examine the impact of previous investigator experience on perceived
barriers to pediatric clinical trial implementation. Our study was lim-
ited by several factors. The nature of our survey is descriptive and de-
pendent on voluntary responses rather than completely representative
of the entire possible group of pediatric providers. Because the survey
email was disseminated in part by asking participants to forward it to
other pediatric practitioners, it was not possible to calculate the survey
response rate. The number of participants with previous experience as
pediatric clinical trial investigators was relatively small, which limited
our ability to detect statistically significant differences between groups
and thus we could only report trends for some cases. We were also
unable to perform multivariable modeling to examine the effect of in-
vestigator experience. Since our data was obtained through a voluntary
survey, we cannot determine if the opinions of individuals who chose
not to participate in the survey would have been different from those
who did participate.
5. Conclusions
Design and implementation of pediatric clinical trials remains dif-
ficult despite new incentivizing legislation for pharmaceutical sponsors.
As a result, children are still relative therapeutic orphans. Involvement
of clinical pediatric providers is crucial to the success of pediatric
clinical trials, but we found that these providers perceive massive
barriers to participating in and referring patients to clinical trials.
Understanding these barriers that prevent providers from collaboration
or inhibit their successful participation is key to designing effective
interventions. Further studies are needed to determine what strategies
can best reduce these barriers or perceptions of these barriers.
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